B.S. in Economics, University Carlos III, Madrid, Spain, 1994; Ph.D. in Health Economics, University of Barcelona, Spain, 2001; M.S. in Clinical Research. Massachusetts College of Pharmacy and Health Sciences, Boston, MA, May 2016
Area(s) of Specialization:
Health Economics and outcomes research; Pharmaceutical economics and policy; Drug utilization and safety; Health and economic impacts of behavioral addictions; Cost-effectiveness analysis of health programs and community-based interventions
My research centers on health economics and outcomes research of health care services and pharmaceuticals. I use large datasets and advanced empirical methods to assess patterns and determinants of prescription drug utilization and safety and drug cost. The overarching goal of my research is to evaluate the cost-effectiveness of health care interventions to enhance equity in access to health care services and pharmaceuticals, improve health outcomes and contain healthcare cost. My current work focuses on assessing the health and economic impacts of behavioral addictions and concurrent mental health disorders.
Rodriguez-Monguio R, Spargo T, Seoane E. Ethical imperatives of timely access to Orphan Drugs: Is possible to reconcile economic incentives and patients' health needs? Orphanet Journal of Rare Diseases. In Press.
Seoane E, Rodriguez-Monguio R. Hansen R. Interchangeability, Safety and Efficacy of Modified Release Drug Formulations in the US: The Case of Opioid and Other Nervous System Drugs. Clin Drug Investig. 2016;36(4):281-92.
Qureshi ZP, Haider MR, Rodriguez-Monguio R, Wooten NR, Ball K, et al. Opioid prescription drug use and expenditures in US outpatient physician offices: Evidence from two nationally representative surveys. Canc Therapy & Oncol Int J. 2017;3(3)
Okunna N,* Rodriguez-Monguio R, Smelson D, Volberg R. An evaluation of substance abuse, mental health disorders, and gambling correlations: An opportunity for early public health interventions. International Journal of Mental Health & Addiction. 2016;14(4):618-633
Kwon CS, Seoane E, Rodriguez-Monguio R. FDA Safety Actions for Antidiabetic Drugs Marketed in the US, 1980-2015. Int J Risk Saf Med. In press.
Hao J,* Rodriguez-Monguio R, Seoane E. Fixed-dose Combination and Single Active Ingredient Drugs: A Comparative Cost Analysis. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):127-34.
* The ﬁrst author was a student and mentee of Dr. Rodriguez-Monguio’s